Importance of Inclusion of Representative Populations in Pivotal Clinical Trials: Zolbetuximab as an Example
Journal of Clinical Oncology · 10.10.2026 · 44 (29) · 2773-2776
DOI: 10.1200/jco-26-01002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.10.2026. Verfasst von Youngwoo Cho und 2 weiteren Autor:innen. Beteiligte Einrichtung: Committee on Clinical Pharmacology and Pharmacogenomics and Center for Personalized Therapeutics, The University of Chicago, Chicago, IL. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Committee on Clinical Pharmacology and Pharmacogenomics and Center for Personalized Therapeutics, The University of Chicago, Chicago, IL.
- H-Consulting, Hamburg, Germany.
- Technical University Munich, Munich, Germany.
- Department of Medicine, The University of Chicago, Chicago, IL.
ORCID-Profile: Youngwoo Cho, Mark J Ratain
Förderung
- NIGMS NIH HHS
Zitieren
APA
Cho, Y., Hanauske, A. R., & Ratain, M. J. (2026). Importance of Inclusion of Representative Populations in Pivotal Clinical Trials: Zolbetuximab as an Example. Journal of Clinical Oncology, 44(29), 2773-2776. https://doi.org/10.1200/jco-26-01002
Vancouver
Cho Y, Hanauske AR, Ratain MJ. Importance of Inclusion of Representative Populations in Pivotal Clinical Trials: Zolbetuximab as an Example. Journal of Clinical Oncology. 2026;44(29):2773-2776. doi:10.1200/jco-26-01002
BibTeX
@article{Cho2026,
author = {Cho, Youngwoo and Hanauske, Axel-R and Ratain, Mark J},
title = {Importance of Inclusion of Representative Populations in Pivotal Clinical Trials: Zolbetuximab as an Example},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {29},
pages = {2773--2776},
doi = {10.1200/jco-26-01002}
}
EUVIMED